

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/gc-22-161	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The data on cardiotoxicity in the treatment of HER-2 positive breast cancer with pyrotinib plus TAC in particular will be shared, we found no obvious changes were revealed in ECG, LVEF, NT-pro-BNP, CK, or CK-MB during the entire treatment process.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, study protocol, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date.
7	To whom will you share the data?	Medical oncologists and breast surgeons who are interested in studies of pyrotinib with TAC regimen.
8	For what type of analysis or purpose?	For analysis to evaluate cardiac safety of pyrotinib with TAC in breast cancer in HER2-positive breast cancer patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: wangweiwei9628@163.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.